BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 19, 2024
See today's BioWorld
Home
» High Number Of Dropouts Spoil Oxytrex Phase III Trial
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
High Number Of Dropouts Spoil Oxytrex Phase III Trial
Nov. 23, 2005
By
Aaron Lorenzo
No Comments
Shares in Pain Therapeutics Inc. lost nearly 20% of their value on news that a Phase III study of Oxytrex was inadequate due to patient dropouts, meaning another trial is in order. (BioWorld Today)
BioWorld
